PGD and chronic myelogenous leukemia, BCR-ABL1 positive: Similar to targeting 6PGD directly, the non-reactive small molecule NADPH analog, β-nicotineamide adenine dinucleotide 3’-phosphate, was effective in models of drug resistance and also inhibited growth of CML and multiple myeloma cancer cell lines.